CAMP4 Therapeutics Corporation
CAMP · NASDAQ
12/31/2024 | 12/31/2023 | 11/30/2023 | 2/28/2023 | |
|---|---|---|---|---|
| Market Cap | $101,817 | $129,977 | – | $386,992 |
| - Cash | $64,039 | $38,380 | – | $83,190 |
| + Debt | $8,648 | $11,693 | – | $12,395 |
| Enterprise Value | $46,426 | $103,290 | – | $316,197 |
| Revenue | $652 | – | $350 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $652 | – | $350 | $0 |
| % Margin | 100% | – | 100% | – |
| EBITDA | -$51,392 | – | -$50,201 | -$44,123 |
| % Margin | -7,882.2% | – | -14,343.1% | – |
| Net Income | -$51,791 | – | -$49,291 | -$44,192 |
| % Margin | -7,943.4% | – | -14,083.1% | – |
| EPS Diluted | -2.66 | – | -4.07 | -0.9 |
| % Growth | – | – | -352.2% | – |
| Operating Cash Flow | -$45,562 | -$44,155 | – | -$38,543 |
| Capital Expenditures | -$441 | -$678 | – | -$4,025 |
| Free Cash Flow | -$46,003 | -$44,833 | – | -$42,568 |